Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, Lionel D Lewis, Todd M Bauer, David F McDermott, Michael Carducci, Christian Kollmannsberger, Brian I Rini, Daniel Y C Heng, Jennifer Knox, Martin H Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J Hammers

ABSTRACT

BACKGROUND: Combination treatment with immune checkpoint inhibitors and antiangiogenic drugs has shown encouraging preliminary antitumor activity across various tumor types including advanced or metastatic renal cell carcinoma (aRCC). The open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and safety of nivolumab in combination with antiangiogenic tyrosine kinase inhibitors or ipilimumab. Long-term outcomes from this study for the combination of nivolumab plus sunitinib or pazopanib in aRCC are presented. METHODS: Patients with aRCC received nivolumab plus either sunitinib (50 mg/day, 4 weeks on/2 weeks off; N + S) or pazopanib (800 mg/day; N + P) until progression/unacceptable toxicity. The nivolumab starting dose was 2 mg/kg every 3 weeks, with planned escalation to 5 mg/kg every 3 weeks. Primary endpoints were safety and tolerability; antitumor activity was a secondary endpoint. RESULTS: Arm N + S enrolled 33 patients, 19 of whom were treatment-naïve; this arm advanced to the expansion phase. Median follow-up was 50.0 months. Patients experienced high frequencies of adverse events (AEs) including treatment-related AEs (100%), grade 3/4 treatment-related AEs (82%), and treatment-related AEs leading to discontinuation (39%). Investigator-assessed objective response rate (ORR) was 55% (18/33) and median progression-free survival (PFS) was 12.7 months. Median overall survival (OS) was not reached. Arm N + P enrolled 20 patients, all had ≥1 prior systemic therapy; this arm was closed due to dose-limiting toxicities and did not proceed to expansion. Median follow-up was 27.1 months. Patients treated with N + P experienced high frequencies of AEs including treatment-related AEs (100%), grade 3/4 treatment-related AEs (70%), and treatment-related AEs leading to discontinuation (25%). Investigator-assessed ORR was 45% (9/20) and median PFS was 7.2 months. Median OS was 27.9 months. CONCLUSIONS: The addition of standard doses of sunitinib or pazopanib to nivolumab resulted in a high incidence of high-grade toxicities limiting future development of either combination regimen. While there was no adverse impact on response and the OS outcome was notable, the findings suggest that the success of combination regimens based on immune checkpoint inhibitors and antiangiogenic drugs may be dependent on careful selection of the antiangiogenic component and dose. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT01472081 . Registered 16 November 2011. More... »

PAGES

109

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40425-018-0420-0

DOI

http://dx.doi.org/10.1186/s40425-018-0420-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1107776066

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30348216


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Levine Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.468189.a", 
          "name": [
            "Immunotherapy program, Levine Cancer Institute, Carolinas HealthCare System, 1024 Morehead Medical Drive, 28204, Charlotte, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Amin", 
        "givenName": "Asim", 
        "id": "sg:person.0616232204.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616232204.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Temple University Health System", 
          "id": "https://www.grid.ac/institutes/grid.412530.1", 
          "name": [
            "Division of Genitourinary Medical Oncology, Department of Hematology/Oncology, Fox Chase Cancer Center, 19111, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Plimack", 
        "givenName": "Elizabeth R", 
        "id": "sg:person.0726044621.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726044621.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roswell Park Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.240614.5", 
          "name": [
            "Division of Oncology, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, 14203, Buffalo, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ernstoff", 
        "givenName": "Marc S", 
        "id": "sg:person.01115160302.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115160302.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dartmouth\u2013Hitchcock Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.413480.a", 
          "name": [
            "Department of Medicine at The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, 03756, Lebanon, NH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lewis", 
        "givenName": "Lionel D", 
        "id": "sg:person.014017277612.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014017277612.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sarah Cannon", 
          "id": "https://www.grid.ac/institutes/grid.419513.b", 
          "name": [
            "Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 37203, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bauer", 
        "givenName": "Todd M", 
        "id": "sg:person.01343430002.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343430002.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Beth Israel Deaconess Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.239395.7", 
          "name": [
            "Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, 02215, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McDermott", 
        "givenName": "David F", 
        "id": "sg:person.0656541200.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656541200.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Johns Hopkins Medicine", 
          "id": "https://www.grid.ac/institutes/grid.469474.c", 
          "name": [
            "Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carducci", 
        "givenName": "Michael", 
        "id": "sg:person.01266317743.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266317743.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "Division of Medical Oncology, British Columbia Cancer Agency, V5Z 4E6, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kollmannsberger", 
        "givenName": "Christian", 
        "id": "sg:person.0660645031.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660645031.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cleveland Clinic Lerner College of Medicine", 
          "id": "https://www.grid.ac/institutes/grid.254293.b", 
          "name": [
            "Lerner College of Medicine, Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, 44195, Cleveland, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rini", 
        "givenName": "Brian I", 
        "id": "sg:person.01113325143.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113325143.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Calgary", 
          "id": "https://www.grid.ac/institutes/grid.22072.35", 
          "name": [
            "Department of Oncology, Tom Baker Cancer Center, University of Calgary, T2N 4N2, Calgary, AB, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heng", 
        "givenName": "Daniel Y C", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Princess Margaret Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.415224.4", 
          "name": [
            "Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, M5G 1Z5, Toronto, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Knox", 
        "givenName": "Jennifer", 
        "id": "sg:person.01270061622.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270061622.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Voss", 
        "givenName": "Martin H", 
        "id": "sg:person.0577111044.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577111044.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Alberta", 
          "id": "https://www.grid.ac/institutes/grid.17089.37", 
          "name": [
            "Department of Oncology, Cross Cancer Institute, University of Alberta, T6G 1Z2, Edmonton, AB, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Spratlin", 
        "givenName": "Jennifer", 
        "id": "sg:person.01275717732.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275717732.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bristol-Myers Squibb (United States)", 
          "id": "https://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "Oncology - Global Clinical Research, Bristol-Myers Squibb, 08541, Princeton, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berghorn", 
        "givenName": "Elmer", 
        "id": "sg:person.01255266321.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255266321.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bristol-Myers Squibb (United States)", 
          "id": "https://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "Oncology - Global Clinical Research, Bristol-Myers Squibb, 08541, Princeton, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yang", 
        "givenName": "Lingfeng", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Internal Medicine, UT Southwestern \u2013 Kidney Cancer Program, 75390, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hammers", 
        "givenName": "Hans J", 
        "id": "sg:person.01220204543.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220204543.52"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.ejca.2016.06.016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001939375"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2016.06.016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001939375"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2015.196", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003895805", 
          "https://doi.org/10.1038/bjc.2015.196"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1740774510382799", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004837970"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1740774510382799", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004837970"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1414428", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007696832"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.59.0703", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009621823"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.58.1041", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010687464"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-1332", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012679517"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.20.1293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013684571"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.5511", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017988502"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1510665", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019970557"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.295.21.2516", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023194691"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.cot.0000482225.33164.30", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024430548"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.cot.0000482225.33164.30", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024430548"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1303989", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030656737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30107-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031150467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-15-2839", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032787294"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.13895", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033899414"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2012.12.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037544552"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.it.2016.04.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041532076"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70465-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043448950"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2015.07.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047619869"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmc1400731", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051518311"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.23.9764", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052849919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1756287215614236", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064077025"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1756287215614236", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064077025"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1756287216663979", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064077045"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1756287216663979", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064077045"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.70.7398", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083840373"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.72.1985", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090362956"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.75.6270", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100100539"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40425-017-0310-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100433878", 
          "https://doi.org/10.1186/s40425-017-0310-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2017.5440", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100916337"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2017.5440", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100916337"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30081-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100960857"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30081-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100960857"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2018.36.6_suppl.578", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101229793"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30107-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101401980"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30107-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101401980"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30107-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101401980"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(18)30107-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101401980"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1712126", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101673751"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2018.36.15_suppl.6016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106715471"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2018.36.15_suppl.tps4598", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106718892"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.35.15_suppl.4505", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106846563"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.35.15_suppl.4506", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106846564"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.35.15_suppl.tps4594", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106850113"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.35.15_suppl.tps4595", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106850114"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.35.15_suppl.tps4597", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106850116"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "BACKGROUND: Combination treatment with immune checkpoint inhibitors and antiangiogenic drugs has shown encouraging preliminary antitumor activity across various tumor types including advanced or metastatic renal cell carcinoma (aRCC). The open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and safety of nivolumab in combination with antiangiogenic tyrosine kinase inhibitors or ipilimumab. Long-term outcomes from this study for the combination of nivolumab plus sunitinib or pazopanib in aRCC are presented.\nMETHODS: Patients with aRCC received nivolumab plus either sunitinib (50\u00a0mg/day, 4\u00a0weeks on/2\u00a0weeks off; N\u2009+\u2009S) or pazopanib (800\u00a0mg/day; N\u2009+\u2009P) until progression/unacceptable toxicity. The nivolumab starting dose was 2\u00a0mg/kg every 3\u00a0weeks, with planned escalation to 5\u00a0mg/kg every 3\u00a0weeks. Primary endpoints were safety and tolerability; antitumor activity was a secondary endpoint.\nRESULTS: Arm N\u2009+\u2009S enrolled 33 patients, 19 of whom were treatment-na\u00efve; this arm advanced to the expansion phase. Median follow-up was 50.0\u00a0months. Patients experienced high frequencies of adverse events (AEs) including treatment-related AEs (100%), grade 3/4 treatment-related AEs (82%), and treatment-related AEs leading to discontinuation (39%). Investigator-assessed objective response rate (ORR) was 55% (18/33) and median progression-free survival (PFS) was 12.7\u00a0months. Median overall survival (OS) was not reached. Arm N\u2009+\u2009P enrolled 20 patients, all had \u22651 prior systemic therapy; this arm was closed due to dose-limiting toxicities and did not proceed to expansion. Median follow-up was 27.1\u00a0months. Patients treated with N\u2009+\u2009P experienced high frequencies of AEs including treatment-related AEs (100%), grade 3/4 treatment-related AEs (70%), and treatment-related AEs leading to discontinuation (25%). Investigator-assessed ORR was 45% (9/20) and median PFS was 7.2\u00a0months. Median OS was 27.9\u00a0months.\nCONCLUSIONS: The addition of standard doses of sunitinib or pazopanib to nivolumab resulted in a high incidence of high-grade toxicities limiting future development of either combination regimen. While there was no adverse impact on response and the OS outcome was notable, the findings suggest that the success of combination regimens based on immune checkpoint inhibitors and antiangiogenic drugs may be dependent on careful selection of the antiangiogenic component and dose.\nTRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT01472081 . Registered 16 November 2011.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s40425-018-0420-0", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "name": "Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study", 
    "pagination": "109", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "72082259eba83aec054d58c073311dbb9fd6a4b1b5389a95e39eb72d1dc41987"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30348216"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101620585"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40425-018-0420-0"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1107776066"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40425-018-0420-0", 
      "https://app.dimensions.ai/details/publication/pub.1107776066"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:53", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000359_0000000359/records_29197_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs40425-018-0420-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-018-0420-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-018-0420-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-018-0420-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-018-0420-0'


 

This table displays all metadata directly associated to this object as RDF triples.

334 TRIPLES      21 PREDICATES      69 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40425-018-0420-0 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N579c745b283c4258a6598f1f96757d35
4 schema:citation sg:pub.10.1038/bjc.2015.196
5 sg:pub.10.1186/s40425-017-0310-x
6 https://doi.org/10.1001/jama.295.21.2516
7 https://doi.org/10.1001/jamaoncol.2017.5440
8 https://doi.org/10.1016/j.ejca.2012.12.010
9 https://doi.org/10.1016/j.ejca.2016.06.016
10 https://doi.org/10.1016/j.eururo.2015.07.006
11 https://doi.org/10.1016/j.it.2016.04.010
12 https://doi.org/10.1016/s1470-2045(13)70465-0
13 https://doi.org/10.1016/s1470-2045(16)30107-3
14 https://doi.org/10.1016/s1470-2045(18)30081-0
15 https://doi.org/10.1016/s1470-2045(18)30107-4
16 https://doi.org/10.1056/nejmc1400731
17 https://doi.org/10.1056/nejmoa1303989
18 https://doi.org/10.1056/nejmoa1414428
19 https://doi.org/10.1056/nejmoa1510665
20 https://doi.org/10.1056/nejmoa1712126
21 https://doi.org/10.1097/01.cot.0000482225.33164.30
22 https://doi.org/10.1158/1078-0432.ccr-08-1332
23 https://doi.org/10.1158/1078-0432.ccr-15-2839
24 https://doi.org/10.1177/1740774510382799
25 https://doi.org/10.1177/1756287215614236
26 https://doi.org/10.1177/1756287216663979
27 https://doi.org/10.1200/jco.2008.19.5511
28 https://doi.org/10.1200/jco.2008.20.1293
29 https://doi.org/10.1200/jco.2009.23.9764
30 https://doi.org/10.1200/jco.2014.58.1041
31 https://doi.org/10.1200/jco.2014.59.0703
32 https://doi.org/10.1200/jco.2016.70.7398
33 https://doi.org/10.1200/jco.2016.72.1985
34 https://doi.org/10.1200/jco.2017.35.15_suppl.4505
35 https://doi.org/10.1200/jco.2017.35.15_suppl.4506
36 https://doi.org/10.1200/jco.2017.35.15_suppl.tps4594
37 https://doi.org/10.1200/jco.2017.35.15_suppl.tps4595
38 https://doi.org/10.1200/jco.2017.35.15_suppl.tps4597
39 https://doi.org/10.1200/jco.2017.75.6270
40 https://doi.org/10.1200/jco.2018.36.15_suppl.6016
41 https://doi.org/10.1200/jco.2018.36.15_suppl.tps4598
42 https://doi.org/10.1200/jco.2018.36.6_suppl.578
43 https://doi.org/10.18632/oncotarget.13895
44 schema:datePublished 2018-12
45 schema:datePublishedReg 2018-12-01
46 schema:description BACKGROUND: Combination treatment with immune checkpoint inhibitors and antiangiogenic drugs has shown encouraging preliminary antitumor activity across various tumor types including advanced or metastatic renal cell carcinoma (aRCC). The open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and safety of nivolumab in combination with antiangiogenic tyrosine kinase inhibitors or ipilimumab. Long-term outcomes from this study for the combination of nivolumab plus sunitinib or pazopanib in aRCC are presented. METHODS: Patients with aRCC received nivolumab plus either sunitinib (50 mg/day, 4 weeks on/2 weeks off; N + S) or pazopanib (800 mg/day; N + P) until progression/unacceptable toxicity. The nivolumab starting dose was 2 mg/kg every 3 weeks, with planned escalation to 5 mg/kg every 3 weeks. Primary endpoints were safety and tolerability; antitumor activity was a secondary endpoint. RESULTS: Arm N + S enrolled 33 patients, 19 of whom were treatment-naïve; this arm advanced to the expansion phase. Median follow-up was 50.0 months. Patients experienced high frequencies of adverse events (AEs) including treatment-related AEs (100%), grade 3/4 treatment-related AEs (82%), and treatment-related AEs leading to discontinuation (39%). Investigator-assessed objective response rate (ORR) was 55% (18/33) and median progression-free survival (PFS) was 12.7 months. Median overall survival (OS) was not reached. Arm N + P enrolled 20 patients, all had ≥1 prior systemic therapy; this arm was closed due to dose-limiting toxicities and did not proceed to expansion. Median follow-up was 27.1 months. Patients treated with N + P experienced high frequencies of AEs including treatment-related AEs (100%), grade 3/4 treatment-related AEs (70%), and treatment-related AEs leading to discontinuation (25%). Investigator-assessed ORR was 45% (9/20) and median PFS was 7.2 months. Median OS was 27.9 months. CONCLUSIONS: The addition of standard doses of sunitinib or pazopanib to nivolumab resulted in a high incidence of high-grade toxicities limiting future development of either combination regimen. While there was no adverse impact on response and the OS outcome was notable, the findings suggest that the success of combination regimens based on immune checkpoint inhibitors and antiangiogenic drugs may be dependent on careful selection of the antiangiogenic component and dose. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT01472081 . Registered 16 November 2011.
47 schema:genre research_article
48 schema:inLanguage en
49 schema:isAccessibleForFree true
50 schema:isPartOf Na7b34feb1cb3495695f2d604ab66dfb7
51 Nd441eef6eadf4999a0951f86931acee4
52 sg:journal.1049249
53 schema:name Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
54 schema:pagination 109
55 schema:productId N0bda31c88dcc4df2a38e5898ab46b173
56 N380282c1e4484f0bb5a07aafdfb1092b
57 N6102fcc550bd45728304877174f28042
58 Naacf8c16a41c4004bbcd0f81f3ea9eb6
59 Nceaa523a2f1747dab2c045b8e2174c27
60 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107776066
61 https://doi.org/10.1186/s40425-018-0420-0
62 schema:sdDatePublished 2019-04-11T11:53
63 schema:sdLicense https://scigraph.springernature.com/explorer/license/
64 schema:sdPublisher Ne557dc94d4e64d7fbb18dca6cbbaade9
65 schema:url https://link.springer.com/10.1186%2Fs40425-018-0420-0
66 sgo:license sg:explorer/license/
67 sgo:sdDataset articles
68 rdf:type schema:ScholarlyArticle
69 N0bda31c88dcc4df2a38e5898ab46b173 schema:name readcube_id
70 schema:value 72082259eba83aec054d58c073311dbb9fd6a4b1b5389a95e39eb72d1dc41987
71 rdf:type schema:PropertyValue
72 N23be5ef83c8d42a68fa395d24a2ef75f rdf:first sg:person.014017277612.37
73 rdf:rest N24d4c6faca4749dab386ffc6e9ff933d
74 N24d4c6faca4749dab386ffc6e9ff933d rdf:first sg:person.01343430002.75
75 rdf:rest Nb674fd6f695e404686aa1c8de0727011
76 N2a801ec4502040fdb9a62657ee80884d rdf:first sg:person.0577111044.36
77 rdf:rest Nd1520755624d46998ea3e0212685f3d3
78 N380282c1e4484f0bb5a07aafdfb1092b schema:name pubmed_id
79 schema:value 30348216
80 rdf:type schema:PropertyValue
81 N3b3b3bf305a049cb9bcc55ef2b9087b4 rdf:first Na03fcd2dbc2a4ba88f3a3010718611f9
82 rdf:rest Nb8b9cfdebb8b4f85b07facf7c909e004
83 N414ee595cf9b47a6a212309b283468a0 rdf:first sg:person.01255266321.73
84 rdf:rest N742d250e8fd94c3084d6a18117c05929
85 N579c745b283c4258a6598f1f96757d35 rdf:first sg:person.0616232204.47
86 rdf:rest Nd7de5bd595d74f349cb53216ce9df0c1
87 N592e58cfa6fe4c83ba97cde816e00cbc rdf:first sg:person.0660645031.33
88 rdf:rest Na77c3bf303fd4f488d40bc24c21e44d9
89 N6102fcc550bd45728304877174f28042 schema:name nlm_unique_id
90 schema:value 101620585
91 rdf:type schema:PropertyValue
92 N742d250e8fd94c3084d6a18117c05929 rdf:first Nab6548b53c434e968b6e1625f13fee73
93 rdf:rest N7adacdec7b09458990d2a984b48faed5
94 N7adacdec7b09458990d2a984b48faed5 rdf:first sg:person.01220204543.52
95 rdf:rest rdf:nil
96 Na03fcd2dbc2a4ba88f3a3010718611f9 schema:affiliation https://www.grid.ac/institutes/grid.22072.35
97 schema:familyName Heng
98 schema:givenName Daniel Y C
99 rdf:type schema:Person
100 Na77c3bf303fd4f488d40bc24c21e44d9 rdf:first sg:person.01113325143.17
101 rdf:rest N3b3b3bf305a049cb9bcc55ef2b9087b4
102 Na7b34feb1cb3495695f2d604ab66dfb7 schema:issueNumber 1
103 rdf:type schema:PublicationIssue
104 Naacf8c16a41c4004bbcd0f81f3ea9eb6 schema:name doi
105 schema:value 10.1186/s40425-018-0420-0
106 rdf:type schema:PropertyValue
107 Nab6548b53c434e968b6e1625f13fee73 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
108 schema:familyName Yang
109 schema:givenName Lingfeng
110 rdf:type schema:Person
111 Nb674fd6f695e404686aa1c8de0727011 rdf:first sg:person.0656541200.82
112 rdf:rest Nc4061abae07c4c82ab4a13f104cf8b53
113 Nb8b9cfdebb8b4f85b07facf7c909e004 rdf:first sg:person.01270061622.88
114 rdf:rest N2a801ec4502040fdb9a62657ee80884d
115 Nc4061abae07c4c82ab4a13f104cf8b53 rdf:first sg:person.01266317743.88
116 rdf:rest N592e58cfa6fe4c83ba97cde816e00cbc
117 Nceaa523a2f1747dab2c045b8e2174c27 schema:name dimensions_id
118 schema:value pub.1107776066
119 rdf:type schema:PropertyValue
120 Nd1520755624d46998ea3e0212685f3d3 rdf:first sg:person.01275717732.80
121 rdf:rest N414ee595cf9b47a6a212309b283468a0
122 Nd441eef6eadf4999a0951f86931acee4 schema:volumeNumber 6
123 rdf:type schema:PublicationVolume
124 Nd7de5bd595d74f349cb53216ce9df0c1 rdf:first sg:person.0726044621.91
125 rdf:rest Ndbf74c9cdb634c018d277de49b2b1e9d
126 Ndbf74c9cdb634c018d277de49b2b1e9d rdf:first sg:person.01115160302.45
127 rdf:rest N23be5ef83c8d42a68fa395d24a2ef75f
128 Ne557dc94d4e64d7fbb18dca6cbbaade9 schema:name Springer Nature - SN SciGraph project
129 rdf:type schema:Organization
130 Nfa032af34c654bd08f96654c8072d839 schema:name Department of Internal Medicine, UT Southwestern – Kidney Cancer Program, 75390, Dallas, TX, USA
131 rdf:type schema:Organization
132 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
133 schema:name Medical and Health Sciences
134 rdf:type schema:DefinedTerm
135 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
136 schema:name Clinical Sciences
137 rdf:type schema:DefinedTerm
138 sg:journal.1049249 schema:issn 2051-1426
139 schema:name Journal for ImmunoTherapy of Cancer
140 rdf:type schema:Periodical
141 sg:person.01113325143.17 schema:affiliation https://www.grid.ac/institutes/grid.254293.b
142 schema:familyName Rini
143 schema:givenName Brian I
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113325143.17
145 rdf:type schema:Person
146 sg:person.01115160302.45 schema:affiliation https://www.grid.ac/institutes/grid.240614.5
147 schema:familyName Ernstoff
148 schema:givenName Marc S
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115160302.45
150 rdf:type schema:Person
151 sg:person.01220204543.52 schema:affiliation Nfa032af34c654bd08f96654c8072d839
152 schema:familyName Hammers
153 schema:givenName Hans J
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220204543.52
155 rdf:type schema:Person
156 sg:person.01255266321.73 schema:affiliation https://www.grid.ac/institutes/grid.419971.3
157 schema:familyName Berghorn
158 schema:givenName Elmer
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255266321.73
160 rdf:type schema:Person
161 sg:person.01266317743.88 schema:affiliation https://www.grid.ac/institutes/grid.469474.c
162 schema:familyName Carducci
163 schema:givenName Michael
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266317743.88
165 rdf:type schema:Person
166 sg:person.01270061622.88 schema:affiliation https://www.grid.ac/institutes/grid.415224.4
167 schema:familyName Knox
168 schema:givenName Jennifer
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270061622.88
170 rdf:type schema:Person
171 sg:person.01275717732.80 schema:affiliation https://www.grid.ac/institutes/grid.17089.37
172 schema:familyName Spratlin
173 schema:givenName Jennifer
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275717732.80
175 rdf:type schema:Person
176 sg:person.01343430002.75 schema:affiliation https://www.grid.ac/institutes/grid.419513.b
177 schema:familyName Bauer
178 schema:givenName Todd M
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343430002.75
180 rdf:type schema:Person
181 sg:person.014017277612.37 schema:affiliation https://www.grid.ac/institutes/grid.413480.a
182 schema:familyName Lewis
183 schema:givenName Lionel D
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014017277612.37
185 rdf:type schema:Person
186 sg:person.0577111044.36 schema:affiliation https://www.grid.ac/institutes/grid.51462.34
187 schema:familyName Voss
188 schema:givenName Martin H
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577111044.36
190 rdf:type schema:Person
191 sg:person.0616232204.47 schema:affiliation https://www.grid.ac/institutes/grid.468189.a
192 schema:familyName Amin
193 schema:givenName Asim
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616232204.47
195 rdf:type schema:Person
196 sg:person.0656541200.82 schema:affiliation https://www.grid.ac/institutes/grid.239395.7
197 schema:familyName McDermott
198 schema:givenName David F
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656541200.82
200 rdf:type schema:Person
201 sg:person.0660645031.33 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
202 schema:familyName Kollmannsberger
203 schema:givenName Christian
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660645031.33
205 rdf:type schema:Person
206 sg:person.0726044621.91 schema:affiliation https://www.grid.ac/institutes/grid.412530.1
207 schema:familyName Plimack
208 schema:givenName Elizabeth R
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726044621.91
210 rdf:type schema:Person
211 sg:pub.10.1038/bjc.2015.196 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003895805
212 https://doi.org/10.1038/bjc.2015.196
213 rdf:type schema:CreativeWork
214 sg:pub.10.1186/s40425-017-0310-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1100433878
215 https://doi.org/10.1186/s40425-017-0310-x
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1001/jama.295.21.2516 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023194691
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1001/jamaoncol.2017.5440 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100916337
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1016/j.ejca.2012.12.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037544552
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1016/j.ejca.2016.06.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001939375
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1016/j.eururo.2015.07.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047619869
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1016/j.it.2016.04.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041532076
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1016/s1470-2045(13)70465-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043448950
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1016/s1470-2045(16)30107-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031150467
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1016/s1470-2045(18)30081-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100960857
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1016/s1470-2045(18)30107-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101401980
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1056/nejmc1400731 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051518311
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1056/nejmoa1303989 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030656737
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1056/nejmoa1414428 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007696832
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1056/nejmoa1510665 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019970557
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1056/nejmoa1712126 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101673751
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1097/01.cot.0000482225.33164.30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024430548
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1158/1078-0432.ccr-08-1332 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012679517
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1158/1078-0432.ccr-15-2839 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032787294
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1177/1740774510382799 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004837970
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1177/1756287215614236 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064077025
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1177/1756287216663979 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064077045
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1200/jco.2008.19.5511 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017988502
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1200/jco.2008.20.1293 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013684571
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1200/jco.2009.23.9764 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052849919
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1200/jco.2014.58.1041 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010687464
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1200/jco.2014.59.0703 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009621823
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1200/jco.2016.70.7398 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083840373
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1200/jco.2016.72.1985 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090362956
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1200/jco.2017.35.15_suppl.4505 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106846563
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1200/jco.2017.35.15_suppl.4506 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106846564
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1200/jco.2017.35.15_suppl.tps4594 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106850113
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1200/jco.2017.35.15_suppl.tps4595 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106850114
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1200/jco.2017.35.15_suppl.tps4597 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106850116
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1200/jco.2017.75.6270 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100100539
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1200/jco.2018.36.15_suppl.6016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106715471
286 rdf:type schema:CreativeWork
287 https://doi.org/10.1200/jco.2018.36.15_suppl.tps4598 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106718892
288 rdf:type schema:CreativeWork
289 https://doi.org/10.1200/jco.2018.36.6_suppl.578 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101229793
290 rdf:type schema:CreativeWork
291 https://doi.org/10.18632/oncotarget.13895 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033899414
292 rdf:type schema:CreativeWork
293 https://www.grid.ac/institutes/grid.17089.37 schema:alternateName University of Alberta
294 schema:name Department of Oncology, Cross Cancer Institute, University of Alberta, T6G 1Z2, Edmonton, AB, Canada
295 rdf:type schema:Organization
296 https://www.grid.ac/institutes/grid.22072.35 schema:alternateName University of Calgary
297 schema:name Department of Oncology, Tom Baker Cancer Center, University of Calgary, T2N 4N2, Calgary, AB, Canada
298 rdf:type schema:Organization
299 https://www.grid.ac/institutes/grid.239395.7 schema:alternateName Beth Israel Deaconess Medical Center
300 schema:name Department of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, 02215, Boston, MA, USA
301 rdf:type schema:Organization
302 https://www.grid.ac/institutes/grid.240614.5 schema:alternateName Roswell Park Cancer Institute
303 schema:name Division of Oncology, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, 14203, Buffalo, NY, USA
304 rdf:type schema:Organization
305 https://www.grid.ac/institutes/grid.248762.d schema:alternateName BC Cancer Agency
306 schema:name Division of Medical Oncology, British Columbia Cancer Agency, V5Z 4E6, Vancouver, BC, Canada
307 rdf:type schema:Organization
308 https://www.grid.ac/institutes/grid.254293.b schema:alternateName Cleveland Clinic Lerner College of Medicine
309 schema:name Lerner College of Medicine, Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, 44195, Cleveland, OH, USA
310 rdf:type schema:Organization
311 https://www.grid.ac/institutes/grid.412530.1 schema:alternateName Temple University Health System
312 schema:name Division of Genitourinary Medical Oncology, Department of Hematology/Oncology, Fox Chase Cancer Center, 19111, Philadelphia, PA, USA
313 rdf:type schema:Organization
314 https://www.grid.ac/institutes/grid.413480.a schema:alternateName Dartmouth–Hitchcock Medical Center
315 schema:name Department of Medicine at The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, 03756, Lebanon, NH, USA
316 rdf:type schema:Organization
317 https://www.grid.ac/institutes/grid.415224.4 schema:alternateName Princess Margaret Cancer Centre
318 schema:name Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, M5G 1Z5, Toronto, ON, Canada
319 rdf:type schema:Organization
320 https://www.grid.ac/institutes/grid.419513.b schema:alternateName Sarah Cannon
321 schema:name Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 37203, Nashville, TN, USA
322 rdf:type schema:Organization
323 https://www.grid.ac/institutes/grid.419971.3 schema:alternateName Bristol-Myers Squibb (United States)
324 schema:name Oncology - Global Clinical Research, Bristol-Myers Squibb, 08541, Princeton, NJ, USA
325 rdf:type schema:Organization
326 https://www.grid.ac/institutes/grid.468189.a schema:alternateName Levine Cancer Institute
327 schema:name Immunotherapy program, Levine Cancer Institute, Carolinas HealthCare System, 1024 Morehead Medical Drive, 28204, Charlotte, NC, USA
328 rdf:type schema:Organization
329 https://www.grid.ac/institutes/grid.469474.c schema:alternateName Johns Hopkins Medicine
330 schema:name Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA
331 rdf:type schema:Organization
332 https://www.grid.ac/institutes/grid.51462.34 schema:alternateName Memorial Sloan Kettering Cancer Center
333 schema:name Department of Medicine, Memorial Sloan Kettering Cancer Center, 10065, New York, NY, USA
334 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...